This clinical trial is focused on studying a condition known as status epilepticus, which is a severe and prolonged seizure that can be life-threatening. The study aims to compare two different treatment approaches for this condition. One approach involves using high doses of medications that help control seizures, known as antiseizure medications. The specific medications being studied include Levetiracetam, Sodium Valproate, Fosphenytoin Sodium, Topiramate, Lacosamide, and Brivaracetam. These medications are administered intravenously, meaning they are given directly into a vein. The other approach involves using medications for rapid sedation, which help calm the brain and body. The medications used for sedation in this study are Propofol and Midazolam, also given intravenously.

The purpose of the study is to determine the effectiveness of rapid sedation with Propofol or Midazolam in an intensive care setting compared to intravenous antiseizure treatment in a hospital ward for patients with a specific type of status epilepticus that is resistant to initial treatments. This type of status epilepticus is referred to as non-convulsive status epilepticus, where the seizures are not accompanied by the typical convulsions or shaking. The study will involve monitoring patients over a period to see how well each treatment works in stopping the seizures and to observe any side effects or complications that may arise.

Participants in the study will receive either the antiseizure medications or the sedation medications, and their progress will be closely monitored by medical professionals. The study will assess various outcomes, such as the number of patients whose seizures continue after 24 hours, any new neurological issues that arise, the length of hospital stay, and overall survival rates after treatment. The goal is to find the most effective and safe treatment option for managing this serious condition.